Adaptive Biotechnologies Corp (NASDAQ: ADPT) has seen a rise in its stock price by 1.63 in relation to its previous close of 10.46. However, the company has experienced a 6.51% gain in its stock price over the last five trading sessions. zacks.com reported 2025-06-11 that Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.
Is It Worth Investing in Adaptive Biotechnologies Corp (NASDAQ: ADPT) Right Now?
The 36-month beta value for ADPT is also noteworthy at 1.79. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for ADPT is 144.91M, and at present, short sellers hold a 6.65% of that float. The average trading volume of ADPT on June 12, 2025 was 2.19M shares.
ADPT’s Market Performance
ADPT stock saw an increase of 6.51% in the past week, with a monthly gain of 11.78% and a quarterly increase of 39.50%. The volatility ratio for the week is 1.41%, and the volatility levels for the last 30 days are 2.01% for Adaptive Biotechnologies Corp (ADPT). The simple moving average for the last 20 days is 11.60% for ADPT stock, with a simple moving average of 55.80% for the last 200 days.
Analysts’ Opinion of ADPT
Many brokerage firms have already submitted their reports for ADPT stocks, with Goldman repeating the rating for ADPT by listing it as a “Buy.” The predicted price for ADPT in the upcoming period, according to Goldman is $9 based on the research report published on March 21, 2025 of the current year 2025.
JP Morgan, on the other hand, stated in their research note that they expect to see ADPT reach a price target of $15. The rating they have provided for ADPT stocks is “Overweight” according to the report published on July 05th, 2023.
Scotiabank gave a rating of “Sector Outperform” to ADPT, setting the target price at $15 in the report published on January 05th of the previous year.
ADPT Trading at 22.93% from the 50-Day Moving Average
After a stumble in the market that brought ADPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.74% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADPT starting from PISKEL KYLE, who sale 1,929 shares at the price of $8.89 back on May 16 ’25. After this action, PISKEL KYLE now owns 277,396 shares of Adaptive Biotechnologies Corp, valued at $17,149 using the latest closing price.
ROBINS HARLAN S, the Chief Scientific Officer of Adaptive Biotechnologies Corp, sale 68,412 shares at $7.35 during a trade that took place back on May 01 ’25, which means that ROBINS HARLAN S is holding 1,279,524 shares at $502,828 based on the most recent closing price.
Stock Fundamentals for ADPT
Current profitability levels for the company are sitting at:
- -0.71 for the present operating margin
- 0.61 for the gross margin
The net margin for Adaptive Biotechnologies Corp stands at -0.75. The total capital return value is set at -0.32. Equity return is now at value -60.96, with -25.08 for asset returns.
Based on Adaptive Biotechnologies Corp (ADPT), the company’s capital structure generated 0.31 points at debt to capital in total, while cash flow to debt ratio is standing at -0.98. The debt to equity ratio resting at 0.46. The interest coverage ratio of the stock is -15.78.
Currently, EBITDA for the company is -128.76 million with net debt to EBITDA at -0.3. When we switch over and look at the enterprise to sales, we see a ratio of 8.71. The receivables turnover for the company is 4.35for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.92.
Conclusion
In summary, Adaptive Biotechnologies Corp (ADPT) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
